In 2023, the antibacterial medicine sales in Belgium stood at 17.8 US Dollars per capita. Moving forward, the forecast projects a progressive decline: 17.3 in 2024, 16.8 in 2025, 16.3 in 2026, 15.7 in 2027, and 15.2 in 2028. Analyzing yearly changes, there is approximately a 2.9% decline from 2023 to 2024, a 2.9% decline in 2025, a 3.0% decline in 2026, a 3.7% drop in 2027, and a 3.2% decrease in 2028. Over the past two years, the compounded annual growth rate (CAGR) averages a drop of 3.14% per year.
Future trends to watch for include potential changes in regulatory policies, shifts towards antibiotic stewardship programs, emergence of resistance, and advancements in alternative treatments. Monitoring these factors will be crucial for anticipating market dynamics.
